← Back to Search

Anti-cancer agents

Polatuzumab Vedotin for Lymphoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called mosunetuzumab combined with standard chemotherapy and another drug called polatuzumab vedotin. Polatuzumab vedotin is approved for treating certain types of lymphoma that have come back or didn't respond to previous treatments, as well as those who haven't been treated before. The treatment works by helping the immune system find and destroy cancer cells and delivering a poison directly to them.

Eligible Conditions
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Active Control
Group I: Phase Ib: Mosunetuzumab (M)-CHOP Dose FindingExperimental Treatment7 Interventions
Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
Group II: Phase Ib: M-CHP-Pola Dose-FindingExperimental Treatment6 Interventions
Participants will receive M-CHP-Pola up to the RP2D.
Group III: Phase II: M-CHP-Pola 1L DLBCLExperimental Treatment6 Interventions
Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
Group IV: Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety CohortExperimental Treatment6 Interventions
Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
Group V: Phase II: M-CHOP 1L DLBCLExperimental Treatment6 Interventions
Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.
Group VI: Phase II: Rituxumab (R)-CHP-Pola 1L DLBCLActive Control5 Interventions
Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Polatuzumab Vedotin
2019
Completed Phase 2
~820
Doxorubicin
2012
Completed Phase 3
~8030
Prednisone
2014
Completed Phase 4
~2500
Vincristine
2003
Completed Phase 4
~2970
Tocilizumab
2012
Completed Phase 4
~1840
Cyclophosphamide
2010
Completed Phase 4
~2310
Mosunetuzumab
2019
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,456 Previous Clinical Trials
1,097,495 Total Patients Enrolled
119 Trials studying Lymphoma
25,594 Patients Enrolled for Lymphoma
Clinical TrialsStudy DirectorHoffmann-La Roche
2,225 Previous Clinical Trials
896,243 Total Patients Enrolled
96 Trials studying Lymphoma
23,850 Patients Enrolled for Lymphoma

Media Library

Cyclophosphamide (Anti-cancer agents) Clinical Trial Eligibility Overview. Trial Name: NCT03677141 — Phase 1 & 2
Lymphoma Research Study Groups: Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL, Phase Ib: M-CHP-Pola Dose-Finding, Phase II: M-CHOP 1L DLBCL, Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding, Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort, Phase II: M-CHP-Pola 1L DLBCL
Lymphoma Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT03677141 — Phase 1 & 2
Cyclophosphamide (Anti-cancer agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03677141 — Phase 1 & 2
~18 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top